This BioNTech Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

• BTIG analyst Julian Harrison upgraded the rating for Aclaris Therapeutics, Inc. ACRS from Neutral to Buy and announced a price target of $8. Aclaris Therapeutics shares closed at $3.14 on Monday. See how other analysts view this stock.
• HSBC analyst Wesley Brooks upgraded the rating for QuantumScape Corporation QS from Reduce to Hold and announced a price target of $5.3. QuantumScape shares closed at $4.73 on Monday. See how other analysts view this stock.
• Evercore ISI Group analyst Cory Kasimov upgraded the rating for BioNTech SE BNTX from In-Line to Outperform and boosted the price target from $110 to $125. BioNTech shares closed at $101.87 on Monday. See how other analysts view this stock.
• Canaccord Genuity analyst Matthew Lee upgraded Bank of Nova Scotia BNS from Hold to Buy and raised the price target from C$71 to C$84. See how other analysts view this stock.
• Jefferies analyst Roger Song upgraded the rating for Aclaris Therapeutics, Inc.  ACRS from Hold to Buy and raised the price target from $2 to $7. Aclaris Therapeutics shares closed at $3.14 on Monday. See how other analysts view this stock.

Considering buying BNTX stock? Here’s what analysts think:

Read This Next:

• Jim Cramer: Super Group Finally ‘Broke Out,’ This Basic Materials Stock Is ‘Very Hard To Own Here’